HUE039878T2 - Regorafenib és acetilszalicilsav kombinációja kolorektális rák kezelésére - Google Patents

Regorafenib és acetilszalicilsav kombinációja kolorektális rák kezelésére

Info

Publication number
HUE039878T2
HUE039878T2 HUE13770659A HUE13770659A HUE039878T2 HU E039878 T2 HUE039878 T2 HU E039878T2 HU E13770659 A HUE13770659 A HU E13770659A HU E13770659 A HUE13770659 A HU E13770659A HU E039878 T2 HUE039878 T2 HU E039878T2
Authority
HU
Hungary
Prior art keywords
regorafenib
combination
colorectal cancer
acetylsalicylic acid
treating colorectal
Prior art date
Application number
HUE13770659A
Other languages
English (en)
Hungarian (hu)
Inventor
Olaf Weber
Karl Ziegelbauer
Original Assignee
Bayer Pharma AG
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE039878(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG, Bayer Ag filed Critical Bayer Pharma AG
Publication of HUE039878T2 publication Critical patent/HUE039878T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE13770659A 2012-09-25 2013-09-23 Regorafenib és acetilszalicilsav kombinációja kolorektális rák kezelésére HUE039878T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12185852 2012-09-25

Publications (1)

Publication Number Publication Date
HUE039878T2 true HUE039878T2 (hu) 2019-02-28

Family

ID=46963566

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13770659A HUE039878T2 (hu) 2012-09-25 2013-09-23 Regorafenib és acetilszalicilsav kombinációja kolorektális rák kezelésére

Country Status (29)

Country Link
US (1) US10898500B2 (pt-PT)
EP (1) EP2900269B1 (pt-PT)
JP (1) JP6294888B2 (pt-PT)
KR (1) KR102210575B1 (pt-PT)
CN (1) CN104994876A (pt-PT)
AU (1) AU2013322854B2 (pt-PT)
BR (1) BR112015006686B1 (pt-PT)
CA (1) CA2885688C (pt-PT)
CL (1) CL2015000744A1 (pt-PT)
CY (1) CY1120939T1 (pt-PT)
DK (1) DK2900269T3 (pt-PT)
EA (1) EA032023B1 (pt-PT)
ES (1) ES2687985T3 (pt-PT)
HK (1) HK1214169A1 (pt-PT)
HR (1) HRP20181462T1 (pt-PT)
HU (1) HUE039878T2 (pt-PT)
IL (1) IL237690B (pt-PT)
LT (1) LT2900269T (pt-PT)
MX (1) MX357035B (pt-PT)
MY (1) MY183969A (pt-PT)
NZ (1) NZ705860A (pt-PT)
PH (1) PH12015500587A1 (pt-PT)
PL (1) PL2900269T3 (pt-PT)
PT (1) PT2900269T (pt-PT)
RS (1) RS57875B1 (pt-PT)
SG (2) SG11201501963RA (pt-PT)
SI (1) SI2900269T1 (pt-PT)
WO (1) WO2014048881A1 (pt-PT)
ZA (1) ZA201502840B (pt-PT)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013276617B9 (en) 2012-06-13 2018-03-29 F. Hoffmann-La Roche Ag New diazaspirocycloalkane and azaspirocycloalkane
SI2900669T1 (sl) 2012-09-25 2019-12-31 F. Hoffmann-La Roche Ag Derivati heksahidropirolo(3,4-C)pirola in sorodne spojine kot zaviralci avtotaksina (ATX) in kot zaviralci tvorbe lizofosfatidne kisline (LPA) za zdravljenje npr. bolezni ledvic
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
MY187449A (en) 2013-11-26 2021-09-22 Hoffmann La Roche New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl
PE20161223A1 (es) 2014-03-26 2016-11-12 Hoffmann La Roche Compuestos condensados de [1,4]diazepina como inhibidores de la produccion de autotaxina (atx) y acido lisofosfatidico (lpa)
DK3122750T3 (da) 2014-03-26 2019-11-04 Hoffmann La Roche Bicykliske forbindelser som autotaxin (ATX)- og lysofosfatidsyre (LPA)-produktionshæmmere
CN103923001B (zh) * 2014-04-30 2016-02-10 药源药物化学(上海)有限公司 瑞戈非尼盐及其晶型、制备方法
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
JP6886967B2 (ja) 2015-09-04 2021-06-16 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft フェノキシメチル誘導体
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
MA42923A (fr) 2015-09-24 2021-04-28 Hoffmann La Roche Composés bicycliques comme inhibiteurs mixtes de atx/ca
CN107614505B (zh) 2015-09-24 2021-05-07 豪夫迈·罗氏有限公司 作为双重atx/ca抑制剂的新型二环化合物
JP6876685B2 (ja) 2015-09-24 2021-05-26 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Atx阻害剤としての二環式化合物
BR112018006024A2 (pt) 2015-09-24 2020-05-12 F. Hoffmann-La Roche Ag Compostos bicíclicos como inibidores de atx
KR102397334B1 (ko) * 2016-06-28 2022-05-11 아사메딕 에이에스 2성분 조성물
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
PT3630112T (pt) 2017-06-02 2024-04-23 Bayer Healthcare Llc Combinação de regorafenib e nivolumab para tratamento de cancro
EP3501522A1 (en) 2017-12-22 2019-06-26 Asamedic AS Compositions comprising acetylsalicylic acid and a phosphate salt
EP3501523A1 (en) 2017-12-22 2019-06-26 Asamedic AS Two-component compositions comprising acetyl salicylic acid and a carbonate salt
KR20210156389A (ko) 2020-06-17 2021-12-27 재단법인대구경북과학기술원 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1197228A4 (en) * 1999-07-02 2004-03-10 Hisamitsu Pharmaceutical Co DRUG COMPOSITIONS FOR THE TREATMENT OF COLORECTAL CANCER
US20040121004A1 (en) 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
DK1663978T3 (da) * 2003-07-23 2008-04-07 Bayer Pharmaceuticals Corp Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
CA2628881A1 (en) * 2005-11-10 2007-05-18 Bayer Healthcare Ag Diaryl urea for treating diabetic neuropathy
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
GB201002530D0 (en) * 2010-02-15 2010-03-31 Univ Wolverhampton The Di-aspirin derivatives
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida

Also Published As

Publication number Publication date
MY183969A (en) 2021-03-17
DK2900269T3 (en) 2018-10-01
MX357035B (es) 2018-06-25
IL237690B (en) 2019-07-31
CY1120939T1 (el) 2019-12-11
SI2900269T1 (sl) 2018-10-30
SG11201501963RA (en) 2015-04-29
PH12015500587A1 (en) 2015-05-11
CA2885688A1 (en) 2014-04-03
ZA201502840B (en) 2017-11-29
CL2015000744A1 (es) 2016-01-08
JP2015529234A (ja) 2015-10-05
CA2885688C (en) 2021-03-02
ES2687985T3 (es) 2018-10-30
HRP20181462T1 (hr) 2018-11-02
AU2013322854B2 (en) 2018-07-19
MX2015003728A (es) 2015-09-23
PL2900269T3 (pl) 2019-02-28
JP6294888B2 (ja) 2018-03-14
US10898500B2 (en) 2021-01-26
HK1214169A1 (zh) 2016-07-22
CN104994876A (zh) 2015-10-21
EA201500365A1 (ru) 2015-08-31
RS57875B1 (sr) 2018-12-31
WO2014048881A1 (en) 2014-04-03
AU2013322854A1 (en) 2015-04-02
KR102210575B1 (ko) 2021-02-02
EP2900269B1 (en) 2018-08-01
BR112015006686A2 (pt) 2019-08-27
IL237690A0 (en) 2015-05-31
PT2900269T (pt) 2018-10-22
KR20150060869A (ko) 2015-06-03
BR112015006686B1 (pt) 2022-04-05
US20150202214A1 (en) 2015-07-23
LT2900269T (lt) 2018-11-12
NZ705860A (en) 2018-07-27
SG10201702356VA (en) 2017-04-27
EP2900269A1 (en) 2015-08-05
EA032023B1 (ru) 2019-03-29

Similar Documents

Publication Publication Date Title
HRP20181462T1 (hr) Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva
IL288181A (en) Cancer treatment methods
HRP20171474T1 (hr) Triazolopirazini kao inhibitori brd4 za uporabu u liječenju raka
HK1209798A1 (en) Compositions and methods for treating cancer
EP2818483A4 (en) MEDICINAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
EP2836482A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
EP2890720A4 (en) COMPOSITIONS AND METHODS OF TREATING CANCER
IL238177A0 (en) Methods and preparations for the treatment of cancer
EP2688594A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
HK1216854A1 (zh) 用於治療癌症的組合物和方法
EP2928456A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2841102A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2822593A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP2902027A4 (en) ACTIVE COMPOSITION FOR THE TREATMENT OF TUMORS AND THE USE THEREOF